Breaking Down Shenyang Xingqi Pharmaceutical Co.,Ltd Financial Health: Key Insights for Investors

Investors hunting for a data-driven snapshot of Shenyang Xingqi Pharmaceutical (300573.SZ) will find striking numbers: H1 2025 operating revenue of 1.163 billion yuan (+30.38% YoY) and net profit attributable to shareholders of 335 million yuan (+97.75% YoY); TTM revenue as of March 31, 2025, is 2.129 billion yuan with quarterly revenue growth of 53.20%, revenue per share TTM of 8.70 yuan and gross profit TTM of 1.682 billion yuan, while operating income TTM is 549.59 million yuan; profitability looks robust with a TTM net profit margin of 21.09%, operating margin of 34.59%, ROA 15.54%, ROE 25.82%, EPS TTM of 1.83 yuan and an EBITDA margin of 36.05%; balance sheet and liquidity show total equity (book) of 1.86 billion yuan (book value per share 7.57 yuan), total debt of 133.91 million yuan and a net cash position of 245.60 million yuan (net cash per share 1.00 yuan) alongside an Altman Z‑Score of 17.9, operating cash flow TTM of 635.84 million yuan, free cash flow of 409.46 million yuan and working capital of 446.37 million yuan (Piotroski F‑Score 5); market valuation sits at a trailing P/E of 26.08, P/S 7.01, P/B 9.09, EV/Revenue 5.82 and EV/EBITDA 19.26, with a dividend yield of 1.12% (annual dividend 0.80 yuan); weigh these strengths against concentration in ophthalmic drugs, raw material and policy risks, and consider growth levers such as the SQ‑129 clinical trial, international expansion and digital health initiatives as you read on for deeper analysis

Shenyang Xingqi Pharmaceutical Co.,Ltd (300573.SZ) - Revenue Analysis

• H1 2025 operating revenue: ¥1.163 billion, up 30.38% year-over-year.
• H1 2025 net profit attributable to shareholders: ¥335 million, up 97.75% year-over-year.
• TTM revenue (as of 2025-03-31): ¥2.129 billion, with quarterly revenue growth of 53.20%.
• Revenue per share (TTM): ¥8.70.
• Gross profit (TTM): ¥1.682 billion, implying a substantial gross margin (gross profit / TTM revenue ≈ 79.0%).
• Operating income (TTM, ending 2025-03-31): ¥549.59 million, indicating operational efficiency and healthy operating margin (operating income / TTM revenue ≈ 25.8%).

• High gross margin (~79%) suggests strong product mix, pricing power, or low COGS relative to sales.
• Operating margin (~25.8%) plus near-doubling of net profit YoY reflects scalable fixed-cost absorption and/or lower operating expenses.
• Revenue per share (¥8.70) combined with robust TTM growth (53.20% quarterly) signals meaningful per-share value creation over the past year.
• Rapid net profit growth (97.75% YoY) indicates improving conversion of revenue into shareholder earnings; monitor sustainability and one-time items.

Shenyang Xingqi Pharmaceutical Co.,Ltd (300573.SZ) Profitability Metrics

For the trailing twelve months (TTM) ending March 31, 2025, Shenyang Xingqi Pharmaceutical exhibits a set of strong profitability indicators that reflect operational efficiency and solid returns to shareholders.

• Net Profit Margin (TTM): 21.09% - indicates effective cost management and solid bottom-line conversion of revenue.
• Operating Margin (TTM): 34.59% - reflects strong core operational performance before non-operating items.
• EBITDA Margin (TTM): 36.05% - highlights robust earnings capacity before depreciation and amortization.
• Return on Assets (ROA, TTM): 15.54% - demonstrates efficient use of company assets to generate profits.
• Return on Equity (ROE, TTM): 25.82% - shows high returns generated on shareholders' equity.
• Earnings Per Share (EPS, TTM): ¥1.83 - earnings attributable to each outstanding share.

These metrics, taken together, signal a company with high operational profitability and efficient capital utilization. For further context on shareholder composition and buying trends, see: Exploring Shenyang Xingqi Pharmaceutical Co.,Ltd Investor Profile: Who's Buying and Why?

Shenyang Xingqi Pharmaceutical Co.,Ltd (300573.SZ) - Debt vs. Equity Structure

Key balance-sheet metrics as of June 30, 2025 demonstrate a capital structure dominated by equity and a strong liquidity cushion.

• Total equity (book value): 1.86 billion yuan
• Book value per share: 7.57 yuan
• Total debt: 133.91 million yuan
• Net cash position: 245.60 million yuan
• Net cash per share: 1.00 yuan
• Altman Z-Score: 17.9 (very low bankruptcy risk)

Interpretation highlights:

• Capital structure is equity-heavy: with 1.86 billion yuan in book equity versus only 133.91 million yuan of debt, leverage is minimal.
• Net cash position of 245.60 million yuan means available liquidity exceeds interest-bearing liabilities, supporting operations, R&D, dividends, or opportunistic M&A.
• Net cash per share (1.00 yuan) provides a clear per-share liquidity floor in addition to the 7.57 yuan book value per share.
• Altman Z-Score of 17.9 signals extremely low financial distress risk; this complements the low debt-to-equity implicit in the figures.
• Equity ratio is implied to be high given the large equity base and net cash - investors can infer a conservative balance-sheet posture.

For further context on shareholder composition and buying trends, see: Exploring Shenyang Xingqi Pharmaceutical Co.,Ltd Investor Profile: Who's Buying and Why?

Shenyang Xingqi Pharmaceutical Co.,Ltd (300573.SZ) - Liquidity and Solvency

Shenyang Xingqi Pharmaceutical demonstrates solid short-term liquidity and operating cash generation, supported by a net cash position and positive working capital. Below are the key metrics for the TTM period ending June 30, 2025 and related solvency indicators.

• Net cash position: reported as net cash (implies short-term liquidity cushions and lower reliance on external short-term financing).
• Current ratio: not directly provided but inferred to be strong given the net cash position and positive working capital.
• Quick ratio: not directly provided but likely strong due to substantial cash and equivalents relative to current liabilities.
• Operating cash flow (TTM ending 2025-06-30): ¥635.84 million - robust cash generation from core operations.
• Free cash flow (same period): ¥409.46 million - indicates solid cash available after capex for debt servicing, dividends, or reinvestment.
• Working capital: ¥446.37 million - positive buffer for short-term obligations and operational needs.
• Piotroski F-Score: 5 - moderate financial strength (mix of strengths and areas for improvement).

Key implications for investors:

• A solid operating cash flow (¥635.84m) and positive free cash flow (¥409.46m) reduce refinancing risk and support capital allocation flexibility.
• Working capital of ¥446.37m and a net cash position provide a cushion against short-term shocks and support ongoing operations and potential strategic investments.
• Piotroski F-Score of 5 signals room for improvement-monitor earnings consistency, leverage trends, and margins to assess movement toward higher financial robustness.

Further context on ownership, trading activity, and investor profile is available here: Exploring Shenyang Xingqi Pharmaceutical Co.,Ltd Investor Profile: Who's Buying and Why?

Shenyang Xingqi Pharmaceutical Co.,Ltd (300573.SZ) - Valuation Analysis

• Trailing P/E: 26.08 - market paying 26.08 times last 12 months' earnings.
• P/S (Price-to-Sales): 7.01 - valuation at 7.01× trailing revenues.
• P/B (Price-to-Book): 9.09 - market values net assets at 9.09× book value.
• EV/Revenue: 5.82 - enterprise value equals 5.82× company revenue.
• EV/EBITDA: 19.26 - enterprise value is 19.26× EBITDA.
• Dividend yield: 1.12% (annual dividend 0.80 CNY per share).

• Implication: Elevated P/E, P/S and P/B together imply investors are pricing in sustained earnings growth, high margins, or strategic intangibles.
• Risk considerations: High multiples increase sensitivity to earnings disappointments or margin compression.
• Income vs. growth: Dividend yield of 1.12% is modest - total return expectations are likely growth-driven.

Shenyang Xingqi Pharmaceutical Co.,Ltd (300573.SZ) - Risk Factors

Shenyang Xingqi Pharmaceutical Co.,Ltd (300573.SZ) operates with concentrated exposure to the ophthalmic medication market and faces multiple risk vectors that can materially affect its financial health. Below are the primary risk factors and quantifiable sensitivities relevant to investors.

• Market concentration: A high percentage of revenue derived from ophthalmic products increases vulnerability to product-specific demand shocks and competitive pressure.
• Regulatory risk: Changes in drug approvals, pricing controls, or clinical requirements in China and export markets can delay product launches or restrict sales.
• Raw material cost volatility: Input price swings (active pharmaceutical ingredients, specialized excipients, packaging) can compress gross margins.
• Execution and integration risk from expansion: M&A, capacity build-outs, or diversification require integration of systems, quality control, and supply chains.
• Healthcare policy and reimbursement changes: Alterations to national insurance formularies, procurement policies, or reimbursement rates affect realized prices and patient access.
• Macroeconomic sensitivity: Economic slowdowns may reduce consumer spending or institutional procurement, particularly for non-acute or elective treatments.
• Foreign exchange exposure: Cross-border sales or imports for raw materials expose profits to CNY volatility versus USD, EUR, and other currencies.

Key operational and financial indicators to monitor closely:

• Revenue mix by product line and customer (hospital vs. retail channels).
• Gross margin trend and pass-through ability for raw material cost increases.
• CAPEX schedule, financing structure, and any contingent liabilities from expansion.
• R&D pipeline milestones and regulatory approval calendar for ophthalmic indications.
• Receivables aging and concentration among major institutional buyers.
• Hedging strategy and currency-denominated exposures.

For additional context on the company's stated strategic priorities and guiding principles, see: Mission Statement, Vision, & Core Values (2026) of Shenyang Xingqi Pharmaceutical Co.,Ltd.

Shenyang Xingqi Pharmaceutical Co.,Ltd (300573.SZ) Growth Opportunities

• Clinical pipeline leverage: SQ-129 clinical-trial approval creates a pathway to market exclusivity in a specialty ophthalmic niche with limited competition.
• Geographic diversification: targeted entry into APAC and selected EM markets could reduce domestic concentration risk and capture higher growth rates outside China.
• Product expansion: advancing additional ophthalmic candidates and adjunct therapies addresses unmet needs in retinal and vitreous disorders.
• Partnerships & collaborations: licensing, co-development and distribution agreements with global ophthalmology firms can accelerate commercialization and de-risk R&D spend.
• Digital & e-commerce investments: tele-ophthalmology tools, digital patient engagement and expanded online pharmacy channels increase access and recurring revenue potential.

• R&D and capital allocation: prioritizing SQ-129 pivotal studies and regulatory submissions (e.g., CFDA/NMPA filings and eventual EMA/FDA pathways) will determine timeline to revenue recognition.
• Partnership models: out-licensing vs co-commercialization tradeoffs - upfront payments, milestones and royalties can accelerate cash flows while sharing development risk.
• Market access & pricing: ophthalmic specialty pricing and reimbursement negotiations in domestic and overseas markets will materially affect realized sales and margins.
• Manufacturing scale-up: investing in GMP capacity for sterile intravitreal formulations or contract manufacturing partnerships is essential to meet projected demand.

• Clinical milestones achieved (phase starts/completions, pivotal trial initiation)
• Estimated time-to-market and regulatory submission dates for SQ-129
• Number and scope of regional distribution/partner agreements
• R&D spend as a % of revenue and incremental margin from new ophthalmic products
• Online channel growth rates (GMV and customer acquisition cost)